公开(公告)号：US20210154281A1

公开(公告)日：2021-05-27

申请号：US17033050

申请日：2020-09-25

申请人： Massachusetts Institute of Technology

发明人： Darrell Irvine ,  Michael Yaffe ,  Ganapathy Sriram ,  Lauren Milling

IPC分类号： A61K39/00 ,  A61K35/15 ,  A61K35/17 ,  A61K45/06 ,  G01N33/50

摘要： Described are cell-based cancer vaccines and anti-cancer immunotherapies. The vaccines include isolated tumor cells activated with one or more genotoxic drugs, and, optionally, treated with one or more MK2 inhibitors. The activated cells are highly immunogenic non-proliferative cells, and may be tested for immunogenicity ex vivo for priming T cells by co-incubating the isolated activated cells with dendritic cells and T cells. The vaccines are typically administered into patient's tumor to provide an intratumoral immune activation. Immune checkpoint inhibitor(s) (ICI) may be administered before, during, or after vaccine administration. ICI may be a component of the vaccine. The vaccines confer heightened cytotoxic immune response against the cancer cells, induce tumor regression, and enhance survival from cancer. The vaccines prevent tumor recurrence and induce a long-lasting anti-tumor immunological memory.